“Adding Mefloquine to An Alzheimer’s Drug is Like Adding Gasoline to a Fire Extinguisher”

As described in this press release, executive director Dr. Nevin has written to Mathieu Charvériat, Scientific Director and Deputy Chief Executive Officer of Paris-based Theranexus, sharing the foundation’s concerns regarding the Theranexus drug candidate THN201, a combination of donepezil and mefloquine, which aims to treat Alzheimer’s disease. Theranexus recently received regulatory approval to begin testing the drug combination in clinical trials.

“Adding mefloquine to an Alzheimer’s drug is like adding gasoline to a fire extinguisher,” said Dr. Nevin. “The last thing a family member would want is for their loved one to suffer the remainder of their lifetime from horrific nightmares and worsened cognitive impairment as a result of their use of a study drug. Yet this is precisely what may happen with attempts to use mefloquine to treat Alzheimer’s disease.”

Thanks to the generous support of its donors, The Quinism Foundation is able to continue work such as this, remaining vigilant to new uses of mefloquine, and educating drug regulators and the pharmaceutical community about the potential dangers of the drug. Your donations make this possible, so please donate now to support these critical education and research efforts.

Support The Quinism Foundation at the 2018 AMSUS Annual Meeting

The Quinism Foundation is honored to have been invited by the scientific committee of the 2018 Annual Meeting of the Association of Military Surgeons of the United States (AMSUS) to give a 50-minute talk to conference attendees on the topic of mefloquine poisoning. The talk will cover how to screen for mefloquine exposure, and how to evaluate patients claiming chronic adverse effects from the drug.

AMSUS does not pay any of the foundation’s expenses in travelling or registering for the conference to be able to give this talk. Your support can help ensure DoD and VA clinicians  in attendance are able to learn from this important information.

Please support this effort — the clinician that attends this talk may be your own!

Are You Among the 1%?

The Quinism Foundation has a mission unlike that of any other non-profit in the world: to support and promote education and research on the medical conditions caused by poisoning by mefloquine and related quinoline drugs. Thanks to our efforts, the disease caused by poisoning of the central nervous system by these drugs now has a name. Chronic quinoline encephalopathy, also known as neuropsychiatric quinism.

Our newsletter now has subscribers around the world — in the United States, Canada, the U.K., Ireland, Australia,  New Zealand, and more — over a dozen countries in all. Every day, individuals affected by chronic quinoline encephalopathy subscribe to our newsletter and join our community.

Yet did you know that only about 1% of our subscribers around the world regularly show their financial support for our efforts?  Are you among the 1%? If so, we thank you. Your financial donations make our volunteer efforts possible.

If every subscriber to this newsletter were to donate just $5, the foundation would have resources we need to support our activities for the remainder of the year. This important work can’t be done without your financial support. Please consider a donation to aid work to support and promote education and research.

The foundation is proud to be listed as a registered charity in the PayPal Giving Fund, on Amazon Smile, and in the Network for Good’s donor-advised fund. You can also read more about the foundation’s charitable activities by reviewing our listing on Guidestar.